# Lung cancer

Source: https://onco.cc/journals/lung-cancer-journal/  
OnCo record `lung-cancer-journal` (Journal). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

The main specialist journal for lung cancer and other chest tumours, publishing trials, translational studies and reviews. Read by thoracic oncologists, surgeons and pulmonologists.

## Summary

Lung Cancer is published by Elsevier and is described on its ScienceDirect page as an international journal for lung cancer and other thoracic malignancies and an official journal of the European Society for Medical Oncology, the ETOP IBCSG Partners Foundation and the British Thoracic Oncology Group; NLM catalogues it under its older subtitle as the journal of the International Association for the Study of Lung Cancer. It covers the clinical, translational and basic science of malignancies of the lung and chest region, welcoming original research articles, early reports, review articles, editorials and correspondence on prevention, epidemiology and aetiology, basic biology, pathology, clinical assessment, surgery, chemotherapy, radiotherapy, combined modality treatment and outcomes. Elsevier lists it as supporting open access with an open archive, with a choice of open access (article publishing charge) or subscription publication. NLM records it as starting in 1985 and currently indexed in MEDLINE.

## Fields

- Kind: Journal
- Last checked: 2026-09-10
- Also known as: Lung cancer : journal of the International Association for the Study of Lung Cancer; Lung Cancer (Amsterdam, Netherlands)
- Publisher: Elsevier
- Scope: thoracic oncology
- Access: hybrid

## Sources

- Homepage: https://www.sciencedirect.com/journal/lung-cancer
- NLM Catalog: https://www.ncbi.nlm.nih.gov/nlmcatalog/8800805

## Connected records

- collections: [PubMed & Europe PMC](https://onco.cc/collections/pubmed-europepmc/)
- cancers: [Mesothelioma](https://onco.cc/cancers/mesothelioma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/), [Thymoma and thymic carcinoma](https://onco.cc/cancers/thymic-epithelial/)
- people: [Nei-Min Chu](https://onco.cc/people/nei-min-chu/)
- key papers: [A phase 2 study of encorafenib in combination with binimetinib for Chinese participants with BRAF V600E mutated metastatic non-small cell lung cancer: Results from the OCEAN II study](https://onco.cc/key-papers/paper-nct05195632-lung-cancer-2026/), [Final overall survival data of sintilimab plus pemetrexed and platinum as First-Line treatment for locally advanced or metastatic nonsquamous NSCLC in the Phase 3 ORIENT-11 study](https://onco.cc/key-papers/paper-orient-11-lung-cancer-2022-update/), [FLAURA2: long-term safety of first-line osimertinib plus platinum-pemetrexed in EGFR-mutated advanced lung cancer](https://onco.cc/key-papers/paper-flaura2-long-term-safety-lung-cancer-2026/)
- companies: [ETOP IBCSG Partners Foundation](https://onco.cc/companies/etop-ibcsg/)

---
JSON: https://onco.cc/api/v1/entities/lung-cancer-journal.json